Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing small molecule therapies for hematologic disorders and cancer. Its approved products include TAVALISSE (fostamatinib), an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia; REZLIDHIA (olutasidenib), an IDH1 inhibitor for relapsed or refractory acute myeloid leukemia; and GAVRETO (pralsetinib), a RET kinase inhibitor for RET fusion-positive non-small cell lung cancer and thyroid cancer. The company also advances R289, a dual IRAK1/4 inhibitor in Phase 1b trials for lower-risk myelodysplastic syndrome. Rigel markets its products in the United States, Europe, the United Kingdom, Japan, South Korea, Canada, and Israel. Strategic collaborations include partnerships with the University of Texas MD Anderson Cancer Center and Eli Lilly for the development of olutasidenib and a RIPK1 inhibitor, respectively. The company acquired rights to GAVRETO from Blueprint Medicines and in-licensed REZLIDHIA from Forma Therapeutics.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage rigel.com
Sector Healthcare IR page rigel.com/investors
Tags
hematologic disorders, cancer, small molecule drugs, immune thrombocytopenia, acute myeloid leukemia, non-small cell lung cancer, thyroid cancer, myelodysplastic syndrome, kinase inhibitors, idh1 inhibitors, ret inhibitors, irak1/4 inhibitors, TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, R289, VEPPANU, fostamatinib, olutasidenib, pralsetinib
Press page rigel.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 906.663M
Market cap (USD) $ 906.663M
P/E 2.99
PEG —
P/BV 2.04
P/S 3.15
P/OCF 10.08
P/FCF 11.98
Dividend yield —
Turnover / mcap —
Returns  
ROE 185.9%
ROI 77.5%
ROIC 26.5%
Profit margin 124.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 11.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 61
Quality score 37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 294.282M 179.278M 116.882M 120.242M 149.236M 108.621M 59.288M 44.509M — — — — — — — — — — — — — — — — 15.303M 13.218M 8.984M
Net profit 367.024M 17.485M -25.091M -58.573M -17.914M -29.744M -66.894M -70.48M -77.992M -69.216M -51.464M -90.908M -89.027M -98.84M -85.973M 37.89M -111.547M -132.346M -74.272M -37.637M -45.256M -56.255M -41.197M -37.03M -23.805M -25.36M -12.366M
Free cash flow 75.655M 31.075M -20.743M -74.208M 5.251M -53.447M -42.965M -59.932M -77.721M -76.693M -23.959M -70.166M -87.282M -88.569M -71.678M 43.183M -102.92M -106.025M -53.14M -36.749M -36.964M -39.697M -33.682M -36.163M -19.21M -15.205M -14.917M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 42.83 16.82 1.45 1.5 2.65 3.5 2.14 2.3 3.88 2.38 3.03 2.27 2.85 6.5 7.86 7.55 — — 9.86 — — — — — — — —
Price performance 12m 1.55 10.6 -0.03 -0.43 -0.24 0.64 -0.07 -0.41 0.63 -0.21 0.33 -0.2 -0.56 -0.17 0.04 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 0.00 0.00 4.08M 10.1M 16M 15.5M 40.3M 30.6M 41.6M 51.8M
↳ YoY growth -100.0% +148.0% +58.0% -3.1% +160.6% -24.2% +36.2% +24.4%
↳ 5y CAGR -6.6% +12.0% +139.4% +49.6% +32.7% +26.5%
Lease liabilities (USD) — — 3.6M 26.5M 19.3M 10.7M 2.11M 977,000 285,000 1.01M
Cash and deposits (USD) 17.6M 38.3M 76.3M 22.5M 30.4M 18.9M 24.5M 32.8M 56.7M 40.6M
Intangible assets (USD) — — — — — — 14.9M 13.9M 27.1M 24.7M
Right-of-use assets (USD) — — — 25.7M 17.9M 9.7M 1.93M 861,000 246,000 920,000
Cash flow detail
Operating cash flow (USD) -75.9M -77.6M -58.8M -41.5M -52.2M 5.88M -73.8M -5.74M 31.5M 75.7M
Purchases of property, plant and equipment (USD) -804,000 -164,000 -1.11M -1.46M -1.26M -627,000 -450,000 — — —
Purchases of intangible assets (USD) — — — — — — — -15M -360,000 0.00
Change in receivables (cash effect) (USD) 203,000 — -4.08M -6.03M -5.86M 501,000 -24.8M 9.77M -11.1M -10.1M
Change in inventories (cash effect) (USD) — — -839,000 -366,000 -126,000 -4.88M -2.38M 1.17M 764,000 -5.64M
Change in payables (cash effect) (USD) 2.8M -2.95M 3.76M -2.24M -331,000 41,000 3.79M -366,000 -3.8M 3.85M
Interest paid (cash effect) (USD) — — — -137,000 -1.18M -1.5M -2.5M -5.85M -7.04M -6.57M
Income taxes paid (cash effect) (USD) — — — — — — — -81,000 -331,000 -1.06M
Share-based compensation (USD) 7.33M 5.99M 7.7M 9.12M 7.3M 9.49M 12.4M 8.81M 12.4M 12.7M
Operating cash flow before change in receivables (USD) -76.1M — -54.7M -35.5M -46.3M 5.38M -48.9M -15.5M 42.5M 85.8M
Free cash flow (OCF - PPE - intangibles) (USD) -76.7M -77.7M -59.9M -43M -53.4M 5.25M -74.2M — — —
Income detail
Research and development expense (USD) 63.4M 46.3M 46.9M 52.9M 60.1M 65.2M 60.3M 24.5M 23.4M 33.3M
↳ 5y CAGR -1.8% -10.1% -9.0% -4.8% -0.9% +0.6% +5.4% -12.2% -15.1% -11.1%
Total comprehensive income (USD) -69.2M -78.1M -70.4M -66.8M -29.8M -18M -58.6M -24.9M 17.5M 367M
Comprehensive income to owners (USD) -69.2M -78.1M -70.4M -66.8M -29.8M -18M -58.6M -24.9M 17.5M 367M
Reported Mar 7, 2017 Mar 6, 2018 May 7, 2019 Feb 27, 2020 Mar 2, 2021 Mar 1, 2022 Mar 7, 2023 Mar 3, 2026 Mar 4, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Rigel Reports Third Quarter 2026 Financial Results Bull 3 Bear 0 Results

Download as PDF November 05, 2026 4:01pm EST

Related Documents

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q Filing

PDF HTML

XBRL

ZIP HTML

  • Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million
  • VEPPANU™ (vepdegestrant) became commercially available in mid-August and generated $6.6 million in initial net product sales for the third quarter
  • The Phase 1b study of R289, Rigel's dual IRAK1/4 inhibitor, in patients with lower-risk MDS is ongoing and Rigel expects to select the recommended Phase 2 dose by the end of 2026
  • Oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS
  • Updated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million
  • Conference call and webcast scheduled today at 4:30 p.m. Eastern Time

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2026, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), REZLIDHIA® (olutasidenib), GAVRETO® (pralsetinib) and VEPPANU™ (vepdegestrant).

"VEPPANU's launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen many refills," said Raul Rodriguez, Rigel's president and CEO. "Our priorities are to build on the VEPPANU launch and advance R289 in lower-risk MDS, with updated Phase 1b data to be presented at ASH in December. We believe VEPPANU and R289 have significant commercial potential to further transform Rigel and drive long-term shareholder value."

Third Quarter 2026 Business Update

Commercial

  • Third quarter net product sales were $72.3 million, an increase of 13% from the same period of 2025.
  • Year-to-date net product sales were $194.2 million, an increase of 17% from the same period of 2025.
  • Rigel announced  that VEPPANU (vepdegestrant) became commercially available in the U.S. on August 13, 2026, generating $6.6 million in net product sales in the third quarter. VEPPANU is the first and only PRoteolysis TArgeting Chimera (PROTAC) approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
  • Rigel's partner Knight Therapeutics Inc. (Knight) received regulatory approval from Colombia's Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in September for TAVALISSE for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.
  • Knight announced it commercially launched TAVALISSE in Brazil in October.

Clinical Development

  • Rigel continues to advance its Phase 1b clinical study of R2891, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS) and the company expects to complete enrollment and select the recommended Phase 2 dose for future development by the end of 2026.
  • Rigel announced  that data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS, including initial efficacy data from the dose expansion phase of the study, will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December. In addition, three poster presentations will include data for fostamatinib in patients with immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA).
  • The European Society for Medical Oncology (ESMO) Congress 2026 featured data from the ARROW and TAPISTRY clinical trials of pralsetinib in patients with rearranged during transfection (RET) fusion-positive solid tumors in a rapid oral session. In addition, two poster presentations and an ePoster included clinical and health-related quality of life (HR-QoL) data from the TAPISTRY clinical trial in patients with RET fusion-positive thyroid cancer and ARROW trial in patients with RET fusion-positive non-small cell lung cancer (NSCLC). 
  • At the 2026 American Thyroid Association (ATA) Annual Meeting, HR-QOL among patients with medullary thyroid cancer and RET fusion-positive thyroid cancer from the ARROW clinical trial of pralsetinib was presented in an oral session, demonstrating that treatment with pralsetinib resulted in clinically meaningful improvements in several measures of HR-QoL for patients, including diarrhea, a common symptom of patients with medullary thyroid cancer and RET fusion-positive thyroid cancer. In addition, data from the ARROW and TAPISTRY clinical trials of pralsetinib in patients with RET fusion-positive thyroid cancer showed robust and durable clinical activity, with an overall response rate of 83.7% and a median progression-free survival of 30.3 months. The safety profile was consistent with previous experience and monitoring for infections is warranted.

Third Quarter and Year-to-Date 2026 Financial Update

For the third quarter ended September 30, 2026, total revenues were $80.9 million, consisting of $72.3 million in net product sales and $8.6 million in contract revenues from collaborations. Net product sales increased 13% compared to $64.1 million in the same period of 2025. TAVALISSE net product sales were $46.0 million, an increase of 3% compared to $44.7 million in the same period of 2025. REZLIDHIA net product sales were $9.9 million, an increase of 20% compared to $8.3 million in the same period of 2025. GAVRETO net product sales were $9.8 million, a decrease of 11% compared to $11.1 million in the same period of 2025. VEPPANU became commercially available from Rigel in August 2026 and generated initial net product sales of $6.6 million. Contract revenues from collaborations primarily consisted of $3.8 million from Grifols S.A. (Grifols) related to earned royalties and delivery of drug supplies, $3.2 million from Kissei Pharmaceutical Co., Ltd. (Kissei) related to delivery of drug supplies, and $0.3 million from Medison Pharma (Medison) and a total of $1.3 million from other parties related to earned royalties and delivery of drug supplies.

Total costs and expenses were $63.8 million, compared to $41.0 million for the same period of 2025. The increase in costs and expenses was primarily driven by higher research and development costs related to the R289 and vepdegestrant clinical programs, cost of product sales, commercial-related expenses due to the commercial launch of vepdegestrant, and personnel-related costs.

Income before income taxes was $17.4 million, compared to $27.6 million for the same period of 2025.

Rigel reported net income of $13.2 million, or $0.70 basic and $0.65 diluted per share, compared to $27.9 million, or $1.55 basic and $1.46 diluted per share, for the same period of 2025.

For the nine months ended September 30, 2026, total revenues were $218.4 million, consisting of $194.2 million in net product sales and $24.2 million in contract revenues from collaborations. Net product sales increased 17% compared to $166.6 million in the same period of 2025. TAVALISSE net product sales were $130.6 million, an increase of 15% compared to $113.3 million in the same period of 2025. GAVRETO net product sales were $30.1 million, a decrease of 6% compared to $31.9 million in the same period of 2025. REZLIDHIA net product sales were $26.9 million, an increase of 25% compared to $21.4 million in the same period of 2025. VEPPANU became commercially available from Rigel in August 2026, and net product sales were $6.6 million. Contract revenues from collaborations primarily consisted of $10.8 million from Kissei, including a $4.0 million regulatory milestone and delivery of drug supplies; $10.5 million from Grifols related to earned royalties and delivery of drug supplies; and $0.9 million from Medison and a total of $2.0 million from other parties related to earned royalties and delivery of drug supplies. Contract revenues from collaborations in the prior year period included $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability from Rigel's collaboration agreement with Eli Lilly and Company (Lilly) and a $3.0 million regulatory milestone in connection with the approval of TAVALISSE in the Republic of Korea.

Total costs and expenses were $165.8 million, compared to $122.2 million for the same period of 2025. The increase in costs and expenses was primarily driven by higher research and development costs related to the R289 and vepdegestrant clinical programs, cost of product sales, personnel-related costs and commercial-related expenses due to the commercial launch of vepdegestrant.

Income before income taxes was $52.7 million, compared to $99.1 million for the same period of 2025.

Rigel reported net income of $39.1 million, or $2.11 basic and $1.97 diluted per share, compared to $99.0 million, or $5.52 basic and $5.38 diluted per share, for the same period of 2025. As noted above, the prior year period included $40.0 million in non-cash revenue related to Rigel's collaboration agreement with Lilly.

Cash, cash equivalents and short-term investments as of September 30, 2026 was $99.3 million, compared to $155.0 million as of December 31, 2025.

2026 Outlook

Rigel has updated its 2026 total revenues guidance to approximately $290 to $295 million, from the previous range of approximately $285 to $295 million, which includes:

  • Net product sales of approximately $255 to $260 million, from the previous range of approximately $255 to $265 million.
  • Contract revenues of approximately $35 million, from the previous guidance of approximately $30 million.

The above revenue guidance excludes VEPPANU. 

The company also continues to anticipate it will report positive net income for the full year 2026, while funding existing and new clinical development programs.

**Conference Call and Webcast with Slides Today at 4:30 p.m. Eastern Time
**Rigel will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Participants can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). The conference call will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com . The webcast will be archived and available for replay after the call via the Rigel website.

About ITP
In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

About AML

Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that there will be about 22,720 new cases in the United States, most in adults, in 2026.2

Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.3,4 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.5 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need.

About NSCLC

It is estimated that over 229,000 adults in the U.S. will be diagnosed with lung cancer in 2026. Lung cancer is the leading cause of cancer death in the U.S., with non-small cell lung cancer (NSCLC) being the most common type accounting for 77% of all lung cancer diagnoses.6 RET fusions are implicated in approximately 1-2% of patients with NSCLC.7

About ER+/HER2-, **ESR1****-mutated Metastatic Breast Cancer
**Breast cancer is the most common cancer in women in the United States, except for skin cancers.8 The estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) patient population represents the majority (70%) of breast cancer, where treatment with endocrine therapies (aromatase inhibitors) is the standard of care. While endocrine therapy remains a cornerstone of metastatic ER+/HER2- breast cancer treatment, up to 50% of patients treated with endocrine therapy and a CDK4/6 inhibitor acquire estrogen receptor 1 gene (ESR1) mutations, resulting in endocrine resistance and poor prognosis. Treatment options in second-line and later ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer setting include chemotherapy, selective estrogen receptor degraders (SERDs), and as of May 2026, vepdegestrant, the first and only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC).

About TAVALISSE**®**
TAVALISSE (fostamatinib disodium hexahydrate) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Please click here  for Important Safety Information and Full Prescribing Information for TAVALISSE.

About REZLIDHIA**®**
REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Please click here for Important Safety Information and Full Prescribing Information, including Boxed WARNING, for REZLIDHIA.

About GAVRETO**®**
GAVRETO is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).*

*Thyroid indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Please click here  for Important Safety Information and Full Prescribing Information, including Boxed WARNING, for GAVRETO.

About VEPPANU™
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

Please click here for Important Safety Information and Full Prescribing Information for VEPPANU.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch  or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE, GAVRETO and REZLIDHIA are registered trademarks and VEPPANU is a trademark of Rigel Pharmaceuticals, Inc.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

  1. R289 is an investigational compound not approved by the FDA.

  2. The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). Revised January 13, 2026. Accessed October 30, 2026: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html

  3. Patel, A, et al. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. 2021 Sep 7;28(7):811-814. doi: https://doi.org/10.3727/096504020X15965357399750  

  4. Thol F, Ganser A. Treatment of Relapsed Acute Myeloid Leukemia. Curr. Treat. Options on Oncol. (2020) 21: 66. doi: https://doi.org/10.1007/s11864-020-00765-5  

  5. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood (2015) 126 (3): 319-27. doi: https://doi.org/10.1182/blood-2014-10-551911

  6. The American Cancer Society. Key Statistics for Lung Cancer. Revised January 13, 2026. Accessed October 30, 2026: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html

  7. Kato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679

  8. The American Cancer Society. Key Statistics for Breast Cancer. Revised June 24, 2026. Accessed October 30, 2026: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to, among other things, Rigel's financial performance and outlook for 2026, including anticipated total revenues, net product sales, contract revenues and profitability; the commercialization of VEPPANU, TAVALISSE, REZLIDHIA and GAVRETO, expected commercial growth and execution of Rigel's commercial strategy; the anticipated timing, progress and results of R289 clinical development, including the anticipated selection of a recommended Phase 2 dose by the end of 2026_; the timing and content of anticipated data presentations; the potential therapeutic benefits of R289 and the other therapies and combinations discussed in this release; Rigel's ability to fund existing and future clinical development programs; and the potential contributions of Rigel's commercial portfolio and development programs to long-term growth and shareholder value. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipates," "believes," "expects," "intends," "may," "plans," "potential," "will" and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. They are based on Rigel's current beliefs, expectations and assumptions and involve significant risks and uncertainties that are difficult to predict and, in many cases, are beyond Rigel's control. Actual results and the timing of events could differ materially from those expressed or implied by these forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the commercialization and marketing of VEPPANU, TAVALISSE, REZLIDHIA and GAVRETO, including physician adoption, patient demand, market acceptance, competition, reimbursement and pricing; risks associated with the transfer and integration of development, manufacturing and commercialization responsibilities for VEPPANU and reliance on Arvinas, Pfizer and other third parties; variability in product sales and the timing and amount of collaboration revenues, expenses and other items affecting financial performance; risks that clinical studies may be delayed, may not be initiated or conducted as anticipated, or may not enroll or retain patients as anticipated; risks that preclinical findings and preliminary or limited clinical data may not be predictive of final results, results in other indications or patient populations, results in subsequent clinical trials or real-world outcomes; risks that additional data, analyses or experience may alter assessments of safety, tolerability, efficacy, dose selection or therapeutic potential; risks that Rigel's products or product candidates, alone or in combination with other therapies, may have unintended side effects or adverse reactions; risks that regulatory authorities may make adverse decisions regarding Rigel's products or development programs, including study designs, dose selection, approvals or continued marketing; risks associated with reliance on third parties for clinical development, manufacturing, supply and other services; the availability and allocation of financial, personnel and other resources; unanticipated business needs or developments that may affect Rigel's funding needs or internal resource requirements; and other risks described in the "Risk Factors" section of Rigel's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and subsequent filings with the Securities and Exchange Commission, including Rigel's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is expected to be filed later today. Any forward-looking statement in this press release speaks only as of the date on which it is made. Rigel undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law._

Download as PDF November 04, 2026 9:15am EST

  • Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS
  • Three poster presentations will highlight data for TAVALISSE_®_ (fostamatinib disodium hexahydrate) in patients with chronic ITP and wAIHA

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday, December 12, 2026. In addition, the ASH Annual Meeting will feature three poster presentations for TAVALISSE® (fostamatinib disodium hexahydrate) in patients with immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The ASH Annual Meeting is taking place from December 12-15, 2026, in New Orleans, Louisiana and virtually.

"Data from the dose escalation phase of the ongoing Phase 1b study of R289 in patients with relapsed or refractory lower-risk MDS was presented at an oral session at last year's ASH," said Alison L. Hannah, M.D., Rigel's chief medical officer. "This year the data from our randomized dose expansion phase will also be presented at an oral session, providing an update on both efficacy, including the reduction of transfusion dependence, and safety. We continue to be encouraged by our evolving data in this heavily pretreated patient population." 

Key highlights from the ASH abstracts include:

  • In the ongoing Phase 1b study of R289 in patients with R/R lower-risk MDS, there were 64 patients enrolled as of July 16, 2026, including 33 patients in the dose escalation phase and 31 patients in the dose expansion phase. At the data cut off, R289 continues to be generally well tolerated in this elderly, heavily pretreated lower-risk MDS patient population, the majority of whom were considered to have high transfusion burden (HTB) disease at baseline. Updated study data as of a planned mid-November data cut will be presented in the oral session, including preliminary efficacy data from the dose expansion phase of the study.
  • In a retrospective real-world analysis of 90 patients with ITP receiving fostamatinib plus a thrombopoietin receptor agonist (TPO-RA), combination treatment was associated with increased platelet counts. Among 38 patients with available measurements during months 7-12, 81.6% had platelet counts ≥50 × 10³/µL, an increase from 33.3% of 90 patients at baseline. These findings support a treatment approach targeting multiple mechanisms of disease through the combination of fostamatinib and TPO-RAs.
  • Data from an interim analysis investigating fostamatinib in 799 patients enrolled in the ongoing post-marketing surveillance in Japan will be presented.  No new safety signals were detected. Platelet counts increased within two weeks of fostamatinib initiation, with responses maintained at 12 months in a subset of patients who continued treatment and had available follow-up data.
  • In an open-label long-term extension study enrolling 71 patients with wAIHA that were treated with fostamatinib, durable hemoglobin responses were observed in >50% of patients during follow-up through Week 104. The long-term safety profile was consistent with the established safety profile of fostamatinib, with no new safety signals identified. Fostamatinib remains investigational in this setting.

ASH Annual Meeting abstracts may be accessed online at www.hematology.org .

Abstract Title Lead Author / Presenter Presentation Type / Publication # Session Title Session Date / Time (CT)
R289
Dose Escalating / Dose Expansion Study of R289, a Dual IRAK 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower Risk Myelodysplastic Syndrome (LR-MDS) Guillermo Garcia-Manero, MD Oral presentation Publication #251 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN Saturday, December 12, 2026 3:00pm – 3:15pm
TAVALISSE (fostamatinib disodium hexahydrate)
Platelet Responses with Combination Therapy of Fostamatinib and Thrombopoietin Receptor Agonists in Immune Thrombocytopenia: An Updated Real-World Analysis David J. Kuter, MD, DPhil Poster presentation Publication #1250 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I Saturday, December 12, 2026 5:30pm – 7:30pm
Real-world safety, effectiveness, and predictors of responses to fostamatinib in patients with ITP: interim analysis of a nationwide post-marketing surveillance in Japan Masataka Kuwana, MD Poster presentation Publication #1252 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I Saturday, December 12, 2026 5:30pm – 7:30pm
Hemoglobin Responses With Fostamatinib in a Long-Term Extension Trial in Warm Autoimmune Hemolytic Anemia David J. Kuter, MD, DPhil Poster presentation Publication #4619 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III Monday, December 14, 20266:00pm – 8:00pm
REZLIDHIA (olutasidenib)
Efficacy of Olutasidenib After Venetoclax in IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Literature Review and Meta-Analysis Jorge E. Cortes, MD Publication only#7191 N/A N/A

About R289
R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, which has been shown in preclinical studies to block inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to various inflammatory conditions. Chronic stimulation of both these receptor systems is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients.2

About ITP
In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

About AML
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that there will be about 22,720 new cases in the United States, most in adults, in 2026.3

Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.4,5 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.6 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need.

About TAVALISSE**®
****Indication
**TAVALISSE (fostamatinib disodium hexahydrate) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

**Important Safety Information
**Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
  • Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to ≥3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
  • Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
  • Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
  • TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.

Drug Interactions

  • Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
  • It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
  • Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
  • Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.

Adverse Reactions

  • Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
  • Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.

Click here for Important Safety Information and Full Prescribing Information**.**

About REZLIDHIA**®**

INDICATION
REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

IMPORTANT SAFETY INFORMATION 

WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include
dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain.
If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and
hemodynamic monitoring until symptom resolution.

WARNINGS AND PRECAUTIONS

**Differentiation Syndrome
**REZLIDHIA can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome occurred in 16% of patients, with grade 3 or 4 differentiation syndrome occurring in 8% of patients treated, and fatalities in 1% of patients. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal. Symptoms of differentiation syndrome in patients treated with REZLIDHIA included leukocytosis, dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, fever, edema, pyrexia, and weight gain. Of the 25 patients who experienced differentiation syndrome, 19 (76%) recovered after treatment or after dose interruption of REZLIDHIA. Differentiation syndrome occurred as early as 1 day and up to 18 months after REZLIDHIA initiation and has been observed with or without concomitant leukocytosis.

If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms.  If concomitant leukocytosis is observed, initiate treatment with hydroxyurea, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms. Differentiation syndrome may recur with premature discontinuation of corticosteroids and/or hydroxyurea treatment. Institute supportive measures and hemodynamic monitoring until improvement; withhold dose of REZLIDHIA and consider dose reduction based on recurrence.

Hepatotoxicity
REZLIDHIA can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory AML who received REZLIDHIA, hepatotoxicity occurred in 23% of patients; 13% experienced grade 3 or 4 hepatotoxicity. One patient treated with REZLIDHIA in combination with azacitidine in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury. The median time to onset of hepatotoxicity in patients with relapsed or refractory AML treated with REZLIDHIA was 1.2 months (range: 1 day to 17.5 months) after REZLIDHIA initiation, and the median time to resolution was 12 days (range: 1 day to 17 months). The most common hepatotoxicities were elevations of ALT, AST, blood alkaline phosphatase, and blood bilirubin.

Monitor patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once every other week for the third month, once in the fourth month, and once every other month for the duration of therapy. If hepatic dysfunction occurs, withhold, reduce, or permanently discontinue REZLIDHIA based on recurrence/severity.

**ADVERSE REACTIONS
**The most common (≥20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea and transaminitis.

DRUG INTERACTIONS

  • Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers.
  • Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing information. If concomitant use is unavoidable, monitor patients for loss of therapeutic effect of these drugs.

LACTATION
Advise women not to breastfeed during treatment with REZLIDHIA and for 2 weeks after the last dose.

**GERIATRIC USE
**No overall differences in effectiveness were observed between patients 65 years and older and younger patients. Compared to patients younger than 65 years of age, an increase in incidence of hepatotoxicity and hypertension was observed in patients ≥65 years of age.

**HEPATIC IMPAIRMENT
**In patients with mild or moderate hepatic impairment, closely monitor for increased probability of differentiation syndrome.

Click here  for Important Safety Information and Full Prescribing Information**, including Boxed WARNING.**

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch  or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE and REZLIDHIA are registered trademarks of Rigel Pharmaceuticals, Inc.

**About Rigel
**Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

  1. R289 is an investigational compound not approved by the FDA.

  2. Sallman DA et al. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. June 16, 2016. doi: https://doi.org/10.3389/fonc.2016.00151

  3. The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). Revised January 13, 2026. Accessed October 30, 2026: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html

  4. Patel, A, et al. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. 2021 Sep 7;28(7):811-814. doi: https://doi.org/10.3727/096504020X15965357399750  

  5. Thol F, Ganser, A. Treatment of Relapsed Acute Myeloid Leukemia. Curr. Treat. Options on Oncol. (2020) 21: 66. doi: https://doi.org/10.1007/s11864-020-00765-5  

  6. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood (2015) 126 (3): 319-27. doi: https://doi.org/10.1182/blood-2014-10-551911

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to, among other things, the anticipated timing and content of presentations at the 2026 American Society of Hematology Annual Meeting and Exposition; the planned data cutoff and availability of updated data from the ongoing Phase 1b study of R289; the progress and potential outcomes of the dose escalation and dose expansion phases of that study; the potential safety, tolerability and efficacy of R289, including its potential to reduce transfusion dependence in patients with lower-risk myelodysplastic syndrome; and the potential therapeutic benefits and clinical utility of fostamatinib in the patient populations and treatment settings described in this release. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipates," "believes," "expects," "intends," "may," "plans," "potential," "will" and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. They are based on Rigel's current beliefs, expectations and assumptions and involve significant risks and uncertainties that are difficult to predict and, in many cases, are beyond Rigel's control. Actual results and the timing of events could differ materially from those expressed or implied by these forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks that clinical studies, data collection, analyses or presentations may be delayed or may not proceed as anticipated; risks that preliminary, interim or limited clinical data may not be predictive of final results, results in larger patient populations or results in subsequent clinical trials; limitations of retrospective, observational, uncontrolled and subgroup analyses, including potential selection bias, confounding factors and incomplete follow-up; risks that clinical trial results may not be predictive of real-world outcomes; risks that additional data, analyses or experience may alter assessments of the safety, tolerability, efficacy or therapeutic potential of R289 or fostamatinib; risks that R289 or fostamatinib may have unintended side effects or adverse reactions; risks that clinical results or decisions by regulatory authorities may not support further development or approval for investigational uses; risks associated with reliance on third parties for clinical development, manufacturing, supply and other services; the availability and allocation of financial, personnel and other resources to fund Rigel's development programs; competition from other therapies; and other risks described in the "Risk Factors" section of Rigel's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement in this press release speaks only as of the date on which it is made. Rigel undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Download as PDF October 29, 2026 8:05am EDT

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com . The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

**About Rigel
**Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

Prompts

Rigel Pharmaceuticals, Inc. (ticker RIGL), listed in United States.

ETFs Holding Rigel Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
AFSM 0.58% 19,296 $ 843.814K Nov 16, 2026
SQLV 0.27% 1,958 $ 76.597K Jun 30, 2026
FTKI 0.22% 1,278 $ 55.887K Nov 16, 2026
BSVO 0.16% 90,456 $ 3.88M Nov 18, 2026
AVUV 0.14% 1,010,343 $ 44.182M Nov 16, 2026
VFMF 0.13% 28,524 $ 1.317M Aug 31, 2026
SEIS 0.11% 16,340 $ 639.221K Jun 30, 2026
FSML 0.09% 3,000 $ 117.36K Jun 30, 2026
PSC 0.09% 50,972 $ 1.994M Jun 30, 2026
FESM 0.06% 91,888 $ 3.595M Jun 30, 2026
AVSC 0.05% 34,196 $ 1.495M Nov 16, 2026
RESM 0.02% 21 $ 821.52 Jun 30, 2026
AVUS 0.01% 18,569 $ 812.022K Nov 16, 2026
AVSU 0.01% 1,135 $ 49.634K Nov 16, 2026
DFAS 0.00% 31,675 $ 1.447M Nov 12, 2026
MSSM 0.00% 632 $ 29.186K Aug 31, 2026
DFAC 0.00% 25,650 $ 1.172M Nov 12, 2026
DCOR 0.00% 5,463 $ 249.604K Nov 12, 2026
DFUV 0.00% 112 $ 5,117.28 Nov 12, 2026